Ching-Yun Hsieh

725 total citations
29 papers, 226 citations indexed

About

Ching-Yun Hsieh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Ching-Yun Hsieh has authored 29 papers receiving a total of 226 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 9 papers in Otorhinolaryngology. Recurrent topics in Ching-Yun Hsieh's work include Lung Cancer Treatments and Mutations (10 papers), Head and Neck Cancer Studies (9 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Ching-Yun Hsieh is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Head and Neck Cancer Studies (9 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Ching-Yun Hsieh collaborates with scholars based in Taiwan, Italy and United States. Ching-Yun Hsieh's co-authors include Ching‐Chan Lin, Chen‐Yuan Lin, Wei‐Chao Chang, Chang‐Fang Chiu, Li‐Yuan Bai, Hsin-Hui Huang, Chi‐Chen Fan, Ling‐Chu Chang, Hung‐Rong Yen and Yung‐An Tsou and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Ching-Yun Hsieh

23 papers receiving 221 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ching-Yun Hsieh Taiwan 9 98 55 40 32 31 29 226
Ching-Shan Luo Taiwan 5 124 1.3× 125 2.3× 84 2.1× 45 1.4× 51 1.6× 8 296
Jean‐François Ramée France 9 160 1.6× 42 0.8× 109 2.7× 28 0.9× 16 0.5× 15 460
Mardiah Suci Hardianti Indonesia 10 99 1.0× 88 1.6× 39 1.0× 16 0.5× 48 1.5× 55 315
Qiang Lin China 12 136 1.4× 57 1.0× 211 5.3× 14 0.4× 10 0.3× 46 333
Katjana Schwab Germany 12 142 1.4× 74 1.3× 53 1.3× 7 0.2× 33 1.1× 23 285
Robert L. Ruxer United States 10 178 1.8× 162 2.9× 129 3.2× 17 0.5× 11 0.4× 13 352
Wan-Lun Hsu Taiwan 6 181 1.8× 104 1.9× 48 1.2× 46 1.4× 29 0.9× 7 355
Caroline Rossoni France 6 113 1.2× 56 1.0× 39 1.0× 27 0.8× 49 1.6× 12 200
Mario Occhipinti Italy 9 163 1.7× 42 0.8× 88 2.2× 10 0.3× 51 1.6× 34 237
Şahin Laçin Türkiye 10 98 1.0× 69 1.3× 38 0.9× 4 0.1× 18 0.6× 37 242

Countries citing papers authored by Ching-Yun Hsieh

Since Specialization
Citations

This map shows the geographic impact of Ching-Yun Hsieh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching-Yun Hsieh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching-Yun Hsieh more than expected).

Fields of papers citing papers by Ching-Yun Hsieh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ching-Yun Hsieh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching-Yun Hsieh. The network helps show where Ching-Yun Hsieh may publish in the future.

Co-authorship network of co-authors of Ching-Yun Hsieh

This figure shows the co-authorship network connecting the top 25 collaborators of Ching-Yun Hsieh. A scholar is included among the top collaborators of Ching-Yun Hsieh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ching-Yun Hsieh. Ching-Yun Hsieh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lin, Ching‐Chan, Wen-Jyi Lo, Ching-Yun Hsieh, et al.. (2024). Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia. Cancers. 16(6). 1082–1082. 2 indexed citations
3.
Huang, Wei‐Chien, et al.. (2024). Stephania tetrandra and Its Active Compound Coclaurine Sensitize NSCLC Cells to Cisplatin through EFHD2 Inhibition. Pharmaceuticals. 17(10). 1356–1356.
4.
Chen, Ji‐Lin, Pei‐Hua Peng, Han‐Tsang Wu, et al.. (2024). ALKBH4 functions as a hypoxia-responsive tumor suppressor and inhibits metastasis and tumorigenesis. Cellular Oncology. 48(2). 425–435.
5.
6.
Hsieh, Ching-Yun, Ching‐Chan Lin, & Wei‐Chao Chang. (2023). Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma. Biomedicines. 11(11). 2887–2887. 7 indexed citations
7.
Chen, Tzu‐Ting, Ching‐Chan Lin, Wen-Jyi Lo, et al.. (2022). Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies. International Journal of Hematology. 115(4). 525–533. 8 indexed citations
8.
Hsieh, Ching-Yun, Ching‐Chan Lin, Yu-Wen Huang, et al.. (2022). Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signaling. JCI Insight. 7(23). 35 indexed citations
9.
Chen, Chia‐Yu, et al.. (2022). Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan. International Journal of Hematology. 117(1). 149–152. 9 indexed citations
10.
Wang, Cheng‐Hsu, K. S. Clifford Chao, Ping‐Tsung Chen, et al.. (2022). PEP503 (NBTXR3), a radioenhancer, in combination with concurrent chemoradiation (CCRT) in locally advanced or recurrent head and neck squamous cell carcinoma (HNSCC): Dose-finding of a phase 1b/2 trial.. Journal of Clinical Oncology. 40(16_suppl). e18041–e18041. 2 indexed citations
11.
Hsieh, Ching-Yun, Liang‐Tsai Hsiao, Yi‐Chang Liu, et al.. (2022). Stem cell transplant for mantle cell lymphoma in Taiwan. Scientific Reports. 12(1). 5662–5662. 2 indexed citations
12.
Chen, Chun‐Chung, Hongwei Li, Yuanliang Wang, et al.. (2022). Patient-derived tumor organoids as a platform of precision treatment for malignant brain tumors. Scientific Reports. 12(1). 16399–16399. 36 indexed citations
13.
14.
Haddad, Robert I., Douglas R. Adkins, Lisa Licitra, et al.. (2021). The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.. Journal of Clinical Oncology. 39(15_suppl). TPS6087–TPS6087. 2 indexed citations
15.
16.
Tu, Chih‐Yen, Te‐Chun Hsia, Hsin‐Yuan Fang, et al.. (2020). Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy. Anticancer Research. 40(10). 5895–5899. 6 indexed citations
17.
Hsieh, Ching-Yun, et al.. (2020). Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study. BMC Cancer. 20(1). 832–832. 16 indexed citations
18.
Chang, Tung‐Ti, et al.. (2016). Integration of Chinese Herbal Medicine Therapy Improves Survival of Patients With Chronic Lymphocytic Leukemia. Medicine. 95(21). e3788–e3788. 17 indexed citations
19.
Mesı́a, Ricard, Paolo Bossi, Aaron R. Hansen, et al.. (2016). Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).. Journal of Clinical Oncology. 34(15_suppl). 6029–6029.
20.
Chitapanarux, Imjai, et al.. (2003). 174 A phase II study of capecitabine in patients who have failed first-line treatment for locally advanced or metastatic cervix cancer (MCC). European Journal of Cancer Supplements. 1(5). S56–S56. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ching-Shan Luo Breakdown of academic impact, for papers by Jean‐François Ramée Breakdown of academic impact, for papers by Mardiah Suci Hardianti Breakdown of academic impact, for papers by Qiang Lin Breakdown of academic impact, for papers by Katjana Schwab Breakdown of academic impact, for papers by Robert L. Ruxer Breakdown of academic impact, for papers by Wan-Lun Hsu Breakdown of academic impact, for papers by Caroline Rossoni Breakdown of academic impact, for papers by Mario Occhipinti Breakdown of academic impact, for papers by Şahin Laçin
Rankless by CCL
2026